COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01008917
Recruitment Status : Completed
First Posted : November 6, 2009
Last Update Posted : May 9, 2019
Northwestern University
Information provided by (Responsible Party):
University of California, San Francisco

Brief Summary:
This is a Phase I study, which means that the goal is to see if the combination of Temsirolimus and Sorafenib is safe in patients with Hepatocellular Carcinoma. Sorafenib is a standard treatment for Hepatocellular Carcinoma. Temsirolimus is used to treat cancer in the kidneys. It is hoped that the addition of Temsirolimus will make Sorafenib more effective against Advanced Hepatocellular Carcinoma, however this can not be guaranteed. The addition of Temsirolimus to Sorafenib is not an FDA approved treatment for Advanced Hepatocellular cancer.

Condition or disease Intervention/treatment Phase
Hepatocellular Carcinoma Drug: sorafenib with temsirolimus Phase 1

Show Show detailed description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 25 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase I Trial of the Combination of Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma
Actual Study Start Date : November 17, 2009
Actual Primary Completion Date : September 12, 2012
Actual Study Completion Date : June 27, 2013

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: single treatment-non randomized study
Phase I study is to test the safety of the combination of sorafenib with temsirolimus at different dose levels
Drug: sorafenib with temsirolimus
Weekly intravenous temsirolimus with daily oral sorafenib
Other Names:
  • Torisel
  • Nexavar

Primary Outcome Measures :
  1. Maximum tolerated dose [ Time Frame: up to 14 months after initial dose ]

Secondary Outcome Measures :
  1. Determine safety/toxicity profile of temsirolimus in combination with sorafenib [ Time Frame: Treatment Period up to 22 cycles estimated to be up to 88 weeks ]
    each cycle is 4 weeks long

  2. Describe pharmacokinetics of temsirolimus alone in the cohort of 6 subjects treated at MTD [ Time Frame: Three cycles of treatment estimated to be 12 weeks ]
    each cycle is 4 weeks long

  3. Describe pharmacokinetics of temsirolimus in combination with sorafenib in the cohort of 6 subjects treated at MTD [ Time Frame: Three cycles of treatment estimated to be 12 weeks ]
    each cycle is 4 weeks long

  4. Incidence of progression-free survival, overall survival, and disease control rate [ Time Frame: 4 weeks (± 5 days) after removal from study or until death, whichever occurs first ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria

  • Histologically or clinically* diagnosed AJCC stage III or IV HCC not amenable to curative resection and with no prior systemic cytotoxic or molecularly-targeted therapies. *Clinical diagnosis is acceptable if tumor meets radiographic criteria.
  • Age ≥ 18 years.
  • Child-Pugh score A or score of B with 7 points only and bilirubin ≤ 2 mg/dL.
  • ECOG performance status ≤ 2.
  • Radiographically measurable disease in at least one site not previously treated with chemoembolization, radioembolization, or other local ablative procedures.
  • Prior chemoembolization, local ablative therapies, or hepatic resection permitted if completed ≥ 6 weeks prior to study enrollment and if criterion 6 is present.
  • Prior radiation for bone or brain metastases is permitted if patient is now asymptomatic and has completed all radiation and steroid therapy (if applicable) for brain or bone metastases ≥ 2 weeks prior to study enrollment.
  • Treatment with appropriate antiviral therapy for patients with active HBV infection is required.
  • Treatment for clinically-significant hyperglycemia, hyperlipidemia, or hypertension that develops on study is required.
  • Baseline blood pressure must be adequately controlled with or without antihypertensive medications prior to enrollment (systolic < 140 mm Hg, diastolic < 90 mm Hg).
  • Baseline cholesterol must be < 350 mg/dL and triglycerides < 300 mg/dL (with or without the use of antihyperlipidemic medications).
  • Baseline fasting blood glucose must be ≤ 140 mg/dL and hemoglobin A1c less than 7% (with or without the use of anti-diabetic medications).
  • Adequate baseline organ and marrow function as defined below:
  • Absolute neutrophil count ≥ 1,500/mcL
  • Platelets ≥ 75,000/mcL
  • Hemoglobin ≥ 8.5 g/dL
  • Total bilirubin ≤ 2 mg/dL or ≤ 1.5 times ULN
  • AST(SGOT)/ALT(SGPT) ≤ 5 times ULN
  • INR ≤ 1.5 times ULN
  • Albumin ≥ 2.8 g/dL
  • Creatinine ≤ 1.5 times ULN
  • Able to tolerate oral therapy.
  • Ability to give written informed consent and willingness to comply with the requirements of the protocol.
  • Effective means of contraception are required in fertile, sexually-active patients.

Exclusion Criteria

  • Mixed tumor histology or fibrolamellar variant tumors are excluded.
  • Prior antiangiogenic therapy (including thalidomide, sorafenib, sunitinib, or bevacizumab).
  • Prior treatment with mTOR inhibitor or other molecularly targeted therapy.
  • Prior systemic cytotoxic therapies for HCC (chemoembolization is permitted if inclusion criteria are met).
  • Treatment with other investigational agents.
  • Immunosuppressive medications including systemic corticosteroids unless used for adrenal replacement, appetite stimulation, acute therapy for asthma or bronchitis exacerbation (≤ 2 weeks), or antiemesis.
  • Patients with known HIV infection are excluded.
  • Patients who have undergone liver transplantation are excluded.
  • Symptomatic brain or bone metastases; prior radiation and/or steroid therapy for brain or bone metastases (if applicable) must be completed ≥ 2 weeks prior to study enrollment.
  • History of seizure disorder requiring antiepileptic medication or brain metastases with seizures.
  • Serious non-healing wound, ulcer, bone fracture, or abscess.
  • Patients requiring chronic anticoagulation with warfarin are excluded. Patients treated with low molecular weight heparin or unfractionated heparin are eligible if on a stable dose without evidence of clinically significant bleeding for at least 2 weeks prior to enrollment.
  • Active second malignancy other than non-melanoma skin cancer or cervical carcinoma in situ.
  • Uncontrolled intercurrent illness.
  • No required concomitant medications with potential for significant interaction with study drugs.
  • Any other condition that compromises compliance with the objectives and procedures of this protocol, as judged by the Study Chair, is also grounds for exclusion.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01008917

Layout table for location information
United States, California
University of California San Francisco
San Francisco, California, United States, 94143
United States, Illinois
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
Chicago, Illinois, United States, 60611
Sponsors and Collaborators
University of California, San Francisco
Northwestern University
Layout table for investigator information
Principal Investigator: Robin K Kelley, MD University of California, San Francisco
Principal Investigator: Alan P Venook, MD University of California, San Francisco
Layout table for additonal information
Responsible Party: University of California, San Francisco Identifier: NCT01008917    
Obsolete Identifiers: NCT01013519
Other Study ID Numbers: CC# 09455
First Posted: November 6, 2009    Key Record Dates
Last Update Posted: May 9, 2019
Last Verified: May 2019
Keywords provided by University of California, San Francisco:
Hepatocellular carcinoma
Liver cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma, Hepatocellular
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Liver Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Liver Diseases
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anti-Bacterial Agents
Anti-Infective Agents
Antibiotics, Antineoplastic
Antifungal Agents
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs